Inovus Medical raises £15M growth round for surgical simulators

Inovus Medical, the St Helens company that builds lifelike surgical simulators from hydrogel, has raised around £15M in growth funding led by NPIF II – PXN Equity Finance, managed by PXN Ventures, to push deeper into US surgical training and new specialities.

Four cheques, one round

The round, announced on 30 September 2026, is led by NPIF II – PXN Equity Finance, part of the British Business Bank’s Northern Powerhouse Investment Fund II and managed by PXN Ventures, which commits around £7M of the total, according to the funding announcement. Mercia, an investor in the company since 2018, follows on, and Hayfin stays in as an existing backer.

Two newer lines complete the stack: Unorthodox Ventures, a Texas-based firm joining as a new investor, and the Liverpool City Region Life Science Innovation Zone, which adds around £1M. The company puts the full raise at roughly $20M at current exchange rates.

The money has a clear destination. Inovus says it will grow its US presence in the general surgery skills market, enter new markets in the Middle East and Asia, extend its simulators into flexible endoscopy and robotic surgery, and grow headcount by around 20%.

“What Elliot and the team have built has the power to transform outcomes for patients around the world by making surgery safer through more modern and intuitive training,” said Louise Chapman of PXN Ventures in the announcement.

Hydrogel organs with a software spine

Founded in 2012 by Dr Elliot Street, a practising surgeon turned CEO, and engineer Jordan Van Flute, Inovus Medical makes anatomical models from hydrogel materials that look, feel and cut like living tissue. Paired with its TOTUM software platform, the simulators track a trainee’s performance and let a mentor review procedures and give feedback remotely – training that would otherwise need an operating theatre, a supervisor and a patient on the table.

The traction is unusually concrete for a company of this size. Its simulators are deployed across the NHS and in nearly 300 US residency programmes, per the company’s announcement, backed by partnerships with the Royal College of Surgeons of England and the American Association of Gynecologic Laparoscopists to deliver standardised training. The US operation runs out of Tampa, Florida.

“We are at an exciting inflexion point for the business,” said Street. “We are now poised to drive commercial growth across our key territories and surgical specialities with this new investment.”

A $176M segment compounding at 14.7%

The market Inovus sells into is small and moving fast: surgical simulation was worth $176.0M in 2025 and is projected to reach $349.4M by 2030, a 14.7% CAGR (MarketsandMarkets, July 2026). Read that against the round and the ambition becomes obvious – a single £15M raise equals roughly a tenth of the segment’s entire 2025 value. Growth capital at that ratio is a bet on category leadership, not on riding a wave.

Our own records give the amount scale. The two European medtech rounds immediately before this one were HighLife’s $90M+ growth round in Paris on 22 September and Anaconda Biomed’s €49.2M raise in Barcelona on 23 September, both tracked in our fundraising database. Devices that go inside patients raise multiples of what devices that train surgeons do. That makes a £15M simulation round the outlier worth noticing, not the footnote.

What St Helens says about medtech money

So why does a £15M round out of St Helens matter more than another nine-figure raise in Paris? Because of where the company sits on the map. We tell ourselves European medtech lives in golden triangles – London, Cambridge, Oxford, or Paris and Munich. The reality is a surgeon-founded company fourteen years in the making, headquartered in a Merseyside town, now selling into nearly 300 American residency programmes.

The good news is the financing sequence that got it there looks repeatable: a regional public-anchored fund leads, the city region’s innovation zone co-invests, and the Texas money arrives once the evidence is in. Public capital first, foreign capital after – that order is quietly becoming the standard for UK medtech outside the capital, and NPIF II exists precisely to run the play again.

Fourteen years from founding to growth round is not a rocket ship; it is the normal tempo of medtech, where evidence compounds more slowly than code. What to watch now is whether the next cheque of this shape lands in another postcode the folklore ignores. The map of European medtech is wider than we keep drawing it – keep watching the north!